77 results
Page 3 of 4
424B5
i1f21af
3 Jun 19
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
rqped3u
21 Mar 19
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
4:40pm
8-K
luo1n3
21 Mar 19
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
4:40pm
424B5
5ip jnrgr
4 May 18
Prospectus supplement for primary offering
6:13am
8-K
EX-1.1
xlx 8omwb3
4 May 18
Sientra Commences Public Offering of Common Stock
6:07am
424B5
ktu3naj6g9cal9d
30 Apr 18
Prospectus supplement for primary offering
7:05am